Table 2 Response to anti-EGFR therapy according to FcγR polymorphisms
FcγRIIIa | FcγRIIa | ||||||
|---|---|---|---|---|---|---|---|
Total no.(%) | V/V | V/F | F/F | H/H | H/R | R/R | |
Response to anti-EGFR based chemotherapy (49 KRAS-wt evaluable pts) | |||||||
CR+PR | 20 (40.8) | 7 | 12 | 1 | 9 | 11 | 0 |
SD | 22 (44.9) | 10 | 11 | 1 | 5 | 13 | 4 |
PD | 7 (14.3) | 1 | 3 | 3 | 3 | 4 | 0 |
P | 0.035 | 0.344 | |||||